JP2022513360A5 - - Google Patents
Info
- Publication number
- JP2022513360A5 JP2022513360A5 JP2021546035A JP2021546035A JP2022513360A5 JP 2022513360 A5 JP2022513360 A5 JP 2022513360A5 JP 2021546035 A JP2021546035 A JP 2021546035A JP 2021546035 A JP2021546035 A JP 2021546035A JP 2022513360 A5 JP2022513360 A5 JP 2022513360A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- here
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811174965.7A CN111018857B (zh) | 2018-10-09 | 2018-10-09 | 靶向蛋白酶降解平台(ted) |
| CN201811174965.7 | 2018-10-09 | ||
| PCT/CN2019/110225 WO2020073930A1 (zh) | 2018-10-09 | 2019-10-09 | 靶向蛋白酶降解平台(ted) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513360A JP2022513360A (ja) | 2022-02-07 |
| JP2022513360A5 true JP2022513360A5 (enExample) | 2022-10-19 |
Family
ID=70164849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546035A Pending JP2022513360A (ja) | 2018-10-09 | 2019-10-09 | 標的プロテアーゼ分解プラットフォーム（ｔｅｄ） |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210369853A1 (enExample) |
| EP (1) | EP3865152A4 (enExample) |
| JP (1) | JP2022513360A (enExample) |
| CN (2) | CN111018857B (enExample) |
| AU (1) | AU2019357908A1 (enExample) |
| CA (1) | CA3115871A1 (enExample) |
| WO (1) | WO2020073930A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| EP3878472A1 (en) * | 2020-03-12 | 2021-09-15 | Julius-Maximilians-Universitaet Wuerzburg | Proteolysis targeting chimera (protac) for degradation of aurora a-kinase |
| US20230158158A1 (en) | 2020-03-27 | 2023-05-25 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
| CN113509557A (zh) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| EP4168410A1 (en) * | 2020-06-22 | 2023-04-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methotrexate analogs and methods of use |
| CN112062768B (zh) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 具有Aurora激酶降解活性的小分子及其制备方法和应用 |
| WO2022165185A1 (en) * | 2021-02-01 | 2022-08-04 | Beth Israel Deaconess Medical Center, Inc. | Cancer-selective target degradation by targeting group caged protacs |
| CN114106010A (zh) * | 2021-04-20 | 2022-03-01 | 上海大学 | 一种蛋白降解靶向嵌合体的制备方法和应用 |
| JP2024526259A (ja) | 2021-07-02 | 2024-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｐｒｏｔａｃ抗体および複合体 |
| CN115594733A (zh) * | 2021-07-09 | 2023-01-13 | 上海大学（Cn） | 化合物、蛋白降解靶向嵌合体及其制备方法和应用 |
| JP7555155B2 (ja) * | 2021-08-10 | 2024-09-24 | オップテラ インコーポレイテッド | 新規ｐｌｋ１分解誘導化合物 |
| CN115894506B (zh) * | 2021-09-30 | 2025-03-18 | 四川大学 | 一种嵌合体分子及其制备方法和用途 |
| CN115960104A (zh) * | 2021-10-09 | 2023-04-14 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解(ted)平台 |
| WO2024086132A1 (en) * | 2022-10-17 | 2024-04-25 | Ohio University | Protacs targeting viral enzymes for precise treatment of covid-19 |
| CN120417934A (zh) * | 2022-12-23 | 2025-08-01 | 基因泰克公司 | Cereblon降解剂缀合物及其用途 |
| IL321713A (en) | 2022-12-27 | 2025-08-01 | Merck Patent Gmbh | Anti-PROTAC VHH antibodies and complexes |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| KR20260023524A (ko) * | 2023-05-18 | 2026-02-20 | 파이어플라이 바이오, 인크. | 이소인돌리논-글루타르이미드 항체 접합체 및 이의 용도 |
| CN117946118A (zh) * | 2024-01-15 | 2024-04-30 | 珃诺生物医药科技(杭州)有限公司 | 一种靶向降解erk5蛋白的化合物及其制备方法 |
| WO2025168071A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物制药（苏州）有限公司 | 一种含氮杂环化合物、其偶联物及其制备方法和用途 |
| WO2025228305A1 (zh) * | 2024-04-28 | 2025-11-06 | 中国科学院上海药物研究所 | 一种蛋白降解剂缀合物及其偶联物 |
| WO2025228947A1 (en) | 2024-04-30 | 2025-11-06 | Crossfire Oncology B.V. | Bifunctional compounds capable of inducing degradation of polo-like kinase1 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010025073A1 (en) * | 2008-08-28 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors |
| BR112016014126B1 (pt) * | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN105085620B (zh) * | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2017246452C1 (en) * | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| US10865205B2 (en) * | 2016-04-22 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use |
| CN109152843A (zh) * | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN107586315B (zh) * | 2016-07-08 | 2020-03-31 | 成都海创药业有限公司 | 一种嵌合分子 |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| CN110753693A (zh) * | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| WO2018227023A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| US20200199247A1 (en) * | 2017-06-07 | 2020-06-25 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
| EP3634960A1 (en) * | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| CN119792569A (zh) * | 2018-01-10 | 2025-04-11 | 财团法人生物技术开发中心 | 抗体protac偶联物 |
| CN109879877B (zh) * | 2019-03-04 | 2021-08-10 | 吉林大学 | 一种可降解plk1和brd4蛋白的化合物及其应用 |
-
2018
- 2018-10-09 CN CN201811174965.7A patent/CN111018857B/zh active Active
-
2019
- 2019-10-09 CA CA3115871A patent/CA3115871A1/en active Pending
- 2019-10-09 JP JP2021546035A patent/JP2022513360A/ja active Pending
- 2019-10-09 AU AU2019357908A patent/AU2019357908A1/en not_active Abandoned
- 2019-10-09 WO PCT/CN2019/110225 patent/WO2020073930A1/zh not_active Ceased
- 2019-10-09 EP EP19872052.6A patent/EP3865152A4/en not_active Withdrawn
- 2019-10-09 US US17/283,892 patent/US20210369853A1/en not_active Abandoned
- 2019-10-09 CN CN201980066587.7A patent/CN112955182A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11318119B2 (en) | HIV protease inhibitors | |
| US20240189335A1 (en) | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | |
| JP2018509468A5 (enExample) | ||
| De Clercq | Antiviral drugs: current state of the art | |
| Betz et al. | Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 | |
| De Clercq | Strategies in the design of antiviral drugs | |
| ES2311921T3 (es) | N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis. | |
| US6410575B2 (en) | Viral treatment | |
| ES2272054T3 (es) | Uso de compuestos de n-sustituido-1,5-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis. | |
| JP2011006419A (ja) | 長時間作用生物活性コンジュゲート | |
| NZ235145A (en) | (substituted-pyrrol)-substituted pyrimidin (di) amines, preparation and pharmaceutical compositions thereof | |
| NO972754D0 (no) | Nukleosidderivater med fotolabile beskyttende grupper | |
| CN111018857A (zh) | 靶向蛋白酶降解平台(ted) | |
| ES2387249T3 (es) | Poliamidas para el tratamiento del virus del papiloma humano | |
| CN114867351A (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| ES2244048T3 (es) | Uso de compuestos (n)-sustituidos-1,5-didesoxi-1,5-imino-d-glucitol en terapia de combinacion para el tratamiento de infecciones con virus de hepatitis. | |
| JP2024515828A5 (enExample) | ||
| HUP0200447A2 (en) | Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JP2008528624A5 (enExample) | ||
| US5137724A (en) | Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines | |
| US20080176817A1 (en) | Compounds Useful in the Treatment of Hiv | |
| CN108210502A (zh) | 治疗逆转录病毒感染的方法和相关剂量方案 | |
| CN104024247B (zh) | 有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺 | |
| US6906190B2 (en) | Inhibitors for de novo-RNA polymerases and methods of identifying targets for same | |
| WO2002056902A2 (en) | Ccr5 antagonist and dp-178 polypeptide for treating viral infections |